Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia
Oncogene, Volume 25, No. 3, Year 2006
Notification
URL copied to clipboard!
Description
Treatments for hematological malignancies have improved considerably over the past decade, but the growing therapeutic arsenal has not benefited adult T-cell leukemia (ATL) patients. Oncolytic viruses such as vesicular stomatitis virus (VSV) have recently emerged as a potential treatment of solid tumors and leukemias in vitro and in vivo. In the current study, we investigated the ability of VSV to lyse primary human T-lymphotropic virus type 1 (HTLV-1)-infected T-lymphocytes from patients with ATL. Ex vivo primary ATL cells were permissive for VSV and underwent rapid oncolysis in a time-dependent manner. Importantly, VSV infection showed neither viral replication nor oncolysis in HTLV-1-infected, nonleukemic cells from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), and in naive CD4+ T-lymphocytes from normal individuals or in ex vivo cell samples from patients with chronic lymphocytic leukemia (CLL). Interestingly, activation of primary CD4+ T-lymphocytes with anti-CD3/CD28 monoclonal antibody, and specifically with anti-CD3, was sufficient to induce limited viral replication and oncolysis. However, at a similar level of T-cell activation, VSV replication was increased fourfold in ATL cells compared to activated CD4+ T-lymphocytes, emphasizing the concept that VSV targets genetic defects unique to tumor cells to facilitate its replication. In conclusion, our findings provide the first essential information for the development of a VSV-based treatment for ATL. © 2006 Nature Publishing Group All rights reserved.
Authors & Co-Authors
Césaire, Raymond
France, Paris
Inserm
Olière, Stéphanie
Canada, Montreal
Sir Mortimer B. Davis Jewish General Hospital
Canada, Montreal
Université Mcgill
Lézin, Agnès
France, Paris
Inserm
Olindo, Stéphane
Martinique, Fort-de-france
Centre Hospitalier Universitaire de Fort de France
Panelatti, Gérard
Martinique, Fort-de-france
Centre Hospitalier Universitaire de Fort de France
Kazanji, Mirdad
French Guiana, Cayenne
Institut Pasteur de la Guyane
Panasci, Lawrence C.
Canada, Montreal
Sir Mortimer B. Davis Jewish General Hospital
Canada, Montreal
Université Mcgill
Hiscott, John B.
Canada, Montreal
Sir Mortimer B. Davis Jewish General Hospital
Canada, Montreal
Université Mcgill
Statistics
Citations: 27
Authors: 8
Affiliations: 6
Identifiers
Doi:
10.1038/sj.onc.1209055
ISSN:
09509232
Research Areas
Cancer
Genetics And Genomics